Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic.
about
Systematic review of economic evaluations of preparedness strategies and interventions against influenza pandemicsAnalysis of 2009 pandemic influenza A/H1N1 outcomes in 19 European countries: association with completeness of national strategic plans.Recommendations for modeling disaster responses in public health and medicine: a position paper of the society for medical decision making.Antiviral resistance during pandemic influenza: implications for stockpiling and drug use.Quarantine for pandemic influenza control at the borders of small island nations.Mitigation of pandemic influenza: review of cost-effectiveness studies.Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic.Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies.Antiviral medications for pregnant women for pandemic and seasonal influenza: an economic computer model.Recommendations for the prevention and treatment of influenza using antiviral drugs based on cost-effectiveness.Pandemic Risk Assessment Model (PRAM): a mathematical modeling approach to pandemic influenza planning.Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts.Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective.The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based studyEvidence synthesis and decision modelling to support complex decisions: stockpiling neuraminidase inhibitors for pandemic influenza usageDynamic modeling for pandemic influenza.Using a Dynamic Model to Consider Optimal Antiviral Stockpile Size in the Face of Pandemic Influenza UncertaintyInfluenza outbreak during Sydney World Youth Day 2008: the utility of laboratory testing and case definitions on mass gathering outbreak containment.Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study.Economic Evidence and Point-of-Care Testing.Cost-effectiveness of pneumococcal vaccines for adults in the United States.Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.Effects of seasonal and pandemic influenza on health-related quality of life, work and school absence in England: results from the Flu Watch cohort study.
P2860
Q28481328-BD2B84CE-4C2E-47B6-9818-7C9069B60B9EQ28709443-BB24F599-5821-4458-A443-9A7057DB9044Q30227771-1DB8C36F-DED2-4078-B3E8-CE08934DE3B5Q30374475-510975CC-1F59-4F87-BC4B-D5B89A05A236Q30375546-2BAA5ED5-D5D0-4AB2-81CA-82A3C2C45B51Q30382889-C76EA0DE-B7C6-4915-89B6-80F561ABB9D8Q30384713-FEBF9D56-E7FE-42B0-8D6D-B5EFCE6E3B77Q30385048-25B462C0-EB51-48A3-A21C-913562F2BCD2Q30385821-1786B2E7-0665-4854-B421-B72DF0CA1A1AQ30390080-DB0C227E-6977-4116-9461-58D89647DF52Q30392042-ECF0D48B-05A3-4E7C-AC45-7AA9885C4987Q30397016-3A02F6C0-DF9B-4B8A-8A97-546B661DD157Q30399379-E722CB8A-C775-4EFE-A6C0-999BFC3C9252Q30400700-19C50426-3669-4E01-BC67-9FFB0486AA42Q30401118-40D3ADBF-3D8E-4707-9630-2D213C41794CQ30419587-3EF45AFF-5C17-49E0-A75E-5F52FBF14B94Q30432474-BE0613B2-5469-4A02-A9D4-16FD5261F659Q33499697-2B750D4A-1041-4558-91E7-B6DA1D6D8BCEQ35803937-C5AE0DC5-225A-4900-9C06-B8DEE1742BE6Q37236078-6C3875DE-DA8A-4FA8-B807-854CEFC3CC4FQ37729902-01827C40-3351-40C2-9EFC-6876ACF436A2Q39175732-0C3FF68F-C66C-4570-8773-BB8BEB3BCF59Q41921626-7E3D0546-83F7-4996-A4B3-3AABDB9839BC
P2860
Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Cost-effectiveness of antivira ...... potential influenza pandemic.
@ast
Cost-effectiveness of antivira ...... potential influenza pandemic.
@en
type
label
Cost-effectiveness of antivira ...... potential influenza pandemic.
@ast
Cost-effectiveness of antivira ...... potential influenza pandemic.
@en
prefLabel
Cost-effectiveness of antivira ...... potential influenza pandemic.
@ast
Cost-effectiveness of antivira ...... potential influenza pandemic.
@en
P2860
P921
P356
P1476
Cost-effectiveness of antivira ...... potential influenza pandemic.
@en
P2093
M Ruby Siddiqui
P2860
P304
P356
10.3201/EID1402.070478
P577
2008-02-01T00:00:00Z